linjc16/ctgov huggingface dataset:
The Relationship Between Serum Endocan and ADMA Levels and Penile Doppler Ultrasonography in Erectile Dysfunction

Study Overview
=================
Brief Summary
-----------------
The gold standard diagnosis in patients admitted to the hospital with the complaint of erectile dysfunction is penile doppler ultrasonography. This procedure is an invasive procedure and can cause various complications. Therefore, in this study, we aimed to support and define the diagnosis of erectile dysfunction with some biomarkers that can be measured in blood samples. At this point, we performed penile doppler ultrasonography, which is the gold standard test, for all patients who applied with the complaint of erectile dysfunction, and compared the results of penile doppler and serum biomarkers in the patients.

Official Title
-----------------
The Relationship Between Serum Endocan and ADMA Levels and Penile Doppler Ultrasonography Findings in Patients With Vasculogenic Erectile Dysfunction

Conditions
-----------------
Evaluation of the Relationship Between Serum Biomarkers (Endocan and ADMA) and Penile Doppler Ultrasonography Findings of Patients With Severe Erectile Dysf

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with severe erectile dysfunction according to International Index of Erectile Function-15 questionnaire Patients who have not received medical or surgical treatment before Patients without comorbidity and related drug use Exclusion Criteria: Patients who have had previous pelvic trauma or surgery, Patients who have benefited from using phosphodiesterase-5 enzyme inhibitors, Patients with psychogenic erectile dysfunction and moderate or mild erectile dysfunction according to International Index of Erectile Function-15 questionnaire, Patients who have neurological disease, chronic liver disease and patients with chronic renal failure and those who used drugs that could cause erectile dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the relationship between serum endocan (endothelial cell-specific molecule-1), ADMA (asymmetric dimethylarginine) values and penile Doppler ultrasonography findings in patients with severe Erectile dysfunction. |  | 10 days from the outpatient clinic admission | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Erectile dysfunction, Endocan, ADMA, Penile Doppler
Radiology Registry on Pancreatic Malignancies

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect all radiological data which evaluated with clinical data may help assess malignancy and prognosis of pancreatic disease.This registry aims to collect retrospective data from 2014 and prospective data until 2027 with a maximum follow-up of 3 years per patient.

Detailed Description
-----------------
Single center, observational (retrospective and prospective) will collect all available parameters to assess the clinical outcome of the patients (progression free survival (PFS), overall survival (OS), local progression free survival LTPFS), response to treatment) with pancreatic neoplasms presenting to San Raffaele. Patient assignment to a given diagnostic and/or therapeutic procedure is not related to random assignment methods but is part of the ordinary therapeutic strategy planned for each patient on an individual basis and after multidisciplinary discussion.

Official Title
-----------------
Radiology Registry on Pancreatic Malignancies

Conditions
-----------------
Pancreatic Cancer, Pancreas Neoplasm, Pancreas Disease, Pancreas Cyst

Intervention / Treatment
-----------------
* Other: Radiology evaluations and interventions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥18 years of age Patients with suspect (planned for investigation) or diagnosed pancreatic cancer at any stage. able and willing to sign informed consent Exclusion Criteria: Patients with non-primary pancreatic disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Radiology evaluations and interventions|Diagnostic and interventional radiology procedures|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression- free survival | Time from start of observation to disease progression | From date of intervention until the date of first documented progression, up to a maximum of 3 years | 
| Local progression free survival | Time between (start of) a locoregional treatment and local disease progression | From date of intervention until the date of first documented local progression assessed up to a maximum of 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Survival | The length of time from either the date of diagnosis or the start of treatment for a disease, in which the patients are still alive | From date of treatment until the date of death from any cause assessed up to 3 years |
Vitamin D Deficiency as a Risk Factor for the Development and Malignant Transformation of Oral Lichen Planus

Study Overview
=================
Brief Summary
-----------------
To investigate the role of Vitamin D (VD) deficiency as a risk factor for the development and malignant transformation of Oral lichen planus (OLP) taking into consideration sex, dietary habits, sun exposure, socioeconomic status and psychological factors.

Official Title
-----------------
Vitamin D Deficiency as a Risk Factor for the Development and Malignant Transformation of Oral Lichen Planus: a Case-control Study

Conditions
-----------------
Oral Lichen Planus, Vitamin D Deficiency

Intervention / Treatment
-----------------
* Device: ELISA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (Group A) patients presenting with a clinical picture and histological findings that confirm the diagnosis of OLP (Group B) age, sex, and dietary habits matched healthy controls. Exclusion Criteria: (1) subjects who have been receiving any kind of VD supplements, multivitamins, or any drug that may affect VD measurements (2) patients with suspected restoration-related or smokeless tobacco-related lesions. (3) patients with any systemic medical condition or pregnant females. (4) patients with VD toxicity (VD≥100 ng/ml).
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A<br>35 OLP patients | Device: ELISA<br>* Enzyme-linked immunosorbent assay (ELISA) was used following manufacturer's instructions. This test uses a competitive ELISA-based technique that was designed to quantitatively determine the concentration of 1,25-dihydroxyvitamin D3/D2 in human serum.<br>|
| Group B<br>35 healthy controls. | Device: ELISA<br>* Enzyme-linked immunosorbent assay (ELISA) was used following manufacturer's instructions. This test uses a competitive ELISA-based technique that was designed to quantitatively determine the concentration of 1,25-dihydroxyvitamin D3/D2 in human serum.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum vitamin D level in OLP | measured by ELISA | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum vitamin D level in correlation with sex, dietary habits and sun exposure. | Questionnaire, measured in proportions | 1 month | 
| serum vitamin D level in correlation with socioeconomic status | Kuppuswamy's socioeconomic status scale | 1 month | 
| serum vitamin D level in correlation with Psychological factors | Depression Anxiety and Stress Scale 21 (DASS-21) | 1 month |
A Cohort of Patients Undergoing Percutaneous Coronary Intervention

Study Overview
=================
Brief Summary
-----------------
To investigate the risk factors involved in the occurrence and prognosis of the patients with acute coronary syndrome, patients undergoing percutaneous coronary intervention will be recruited and followed up for at least 2 years.

Detailed Description
-----------------
Patients with acute coronary syndrome undergoing percutaneous coronary intervention will be recruited and prospectively followed up for the incidence of major adverse cardiovascular events (MACE events), including all-cause mortality, cardiovascular mortality, ischemic stroke. Blood and fecal samples will be collected for further analysis. The basic and clinical information will be collected such as diagnosis, medical history, laboratory test results, therapy methods, prognosis and follow-up information. The risk factors involved in the occurrence and prognosis of acute coronary syndrome will be investigated.

Official Title
-----------------
A Longitudinal Cohort of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Conditions
-----------------
Acute Coronary Syndrome, Percutaneous Coronary Intervention, Myocardial Infarction, Unstable Angina

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed as acute coronary syndrome and needed to undergo percutaneous coronary intervention. >18 years old. Exclusion Criteria: With malignant tumors, acute infectious diseases and advanced liver diseases. Won't sign an inform consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| major adverse cardiovascular events | all-cause mortality, cardiovascular mortality, ischemic stroke | 2-year outcome and long-term outcome |
The Proactive Diagnostic Value of Hemostatic Biomarkers in Disseminated Intravascular Coagulation

Study Overview
=================
Brief Summary
-----------------
The project was undertaking by Qilu Hospital of Shandong University, aiming to evaluate diagnostic performance of hemostatic biomarkers in disseminated intravascular coagulation.

Detailed Description
-----------------
Disseminated intravascular coagulation (DIC) is a life-threatening condition with high mortality, necessitating timely and accurate diagnosis for effective management. However, current diagnostic systems can not recognize DIC at its reversible phase, causing suboptimal treatment outcomes. Consequently, the current diagnostic criteria for DIC lacks earlier laboratory indicators. Therefore, the investigators aimed to assess the diagnostic potential of selected hemostatic biomarkers, including thrombin-antithrombin complex (TAT), soluble thrombomodulin (sTM), tissue plasminogen activator inhibitor complex (tPAI-C), α2-plasmin inhibitor plasmin complex (PIC) and anti-thrombin III (ATIII), in evaluating DIC, allowing for proactive diagnosis before the disease progresses into its irreversible phase.

Official Title
-----------------
The Proactive Diagnostic Value of Hemostatic Biomarkers in Disseminated Intravascular Coagulation

Conditions
-----------------
Disseminated Intravascular Coagulation

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years old, non-perinatal period, a hospitalization length of≥3 days. Exclusion Criteria: primary hematologic diseases, decompensated liver cirrhosis, chemotherapy history.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 94 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| non-DIC group<br> | Other: no intervention<br>* no intervention<br>|
| pre-DIC group<br> | Other: no intervention<br>* no intervention<br>|
| overt-DIC group<br> | Other: no intervention<br>* no intervention<br>|
| DIC group<br> | Other: no intervention<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| whether DIC occured | DIC includes pre-DIC and overt-DIC | From date of detecting hemostatic biomarkers until the date of first ISTH-DIC scores ≥5, assessed up to 7 days. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| whether death occurred | Based on the death records in the electronic medical records | From date of admission until the date of death, assessed up to 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thrombosis, Coagulation, Hemostatic Biomarkers, DIC
Evaluating Factors In Study Experiences of Lymphedema Patients

Study Overview
=================
Brief Summary
-----------------
The study intends to investigate the personal experiences of lymphedema patients who take part in a separate clinical trial including a specific medication intervention. The major focus will be on closely following individuals' rates of trial completion and withdrawal. The data collected from this study will help improve future outcomes for all lymphedema patients as well as those in under-represented demographic groups.

Official Title
-----------------
Exploring the Real-life Stories of Individuals Enrolled in Lymphedema Clinical Trials

Conditions
-----------------
Lymphedema

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with lymphedema Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination. Exclusion Criteria: Refusal of consent Women of childbearing potential without a negative pregnancy test; or women who are lactating. Any serious and/or unstable pre-existing medical disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who decide to enroll in a lymphedema clinical trial |  | 3 months | 
| Rate of patients who remain in lymphedema clinical trial to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lymphedema
Cohort Study of Chronic Heart Failure

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to learn about the influencing factors of chronic heart failure prognosis in heart failure patients. The main question it aims to answer is that what are the influencing factors of clinical outcomes in chronic heart failure. Participants will be collected multiple omics data such as phenotype group, environmental exposure group, intestinal microbiome, genome, metabolome, and noninvasive biomarkers.

Official Title
-----------------
Cohort Study of Chronic Heart Failure

Conditions
-----------------
Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 18 years old Dilated cardiomyopathy, hypertensive cardiomyopathy, ischemic cardiomyopathy (coronary heart disease), non-severe valvular heart disease LVEF<50%, and/or NT-proBNP>1800ng/L, and/or BNP>100ng/L, NYHA I-III grade Able to understand and sign informed consent forms Exclusion Criteria: Expected life less than 3 months Patients with severe renal insufficiency (Ccr<30ml/min) or undergoing dialysis treatment Cardiac insufficiency caused by various secondary causes that can be corrected includes hyperthyroid heart disease, anemic heart disease, and uncorrected Congenital heart defect Presence of indications for pacemaker implantation and absence of pacemaker implantation Chronic obstructive pulmonary disease with type II Respiratory failure Special populations such as mental illness patients and pregnant women Unable to understand and sign informed consent form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite endpoint of cardiovascular death and rehospitalization for heart failure | Cardiovascular disease death and heart failure readmission are two endpoint events, with either occurring as the primary endpoint | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all-cause mortality | all-cause mortality | 2 years |
A Biomarker Study for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients

Study Overview
=================
Brief Summary
-----------------
dMMR/MSI-H colorectal cancer patients are the dominant population of immunotherapy/neoadjuvant immunotherapy, but imaging evaluation of immunotherapy efficacy is insufficient. There are some cases, although no disease remission was found on imaging,pathological complete response (pCR) was confirmed after surgery. Meanwhile,previous studies have shown that dynamic changes in ctDNA can help assess immunotherapy efficacy. Therefore, we propose to conduct a multicenter, prospective, observational clinical study to explore the efficacy prediction and monitoring value of ctDNA in immunotherapy for advanced or locally advanced dMMR/MSI-H colorectal cancer.

Official Title
-----------------
Study on the Clinical Potential of Circulating Tumor DNA in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients Treated With Immunotherapy

Conditions
-----------------
Colorectal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - advanced or locally advanced dMMR/MSI-H colorectal cancer Expected to receive/be receiving immune checkpoint inhibitor therapy ECOG performance score is 0-1, life expectancy ≥12 weeks Exclusion Criteria: - The presence of other uncured malignancies Patients with one or more serious concomitant systemic diseases that, in the investigator's opinion, impair the patient's ability to complete the study Patients with autoimmune disease are not suitable for PD1 monoclonal antibody therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of ctDNA changes with pCR rate and the duration of cCR | Correlation of ctDNA changes with rate of pathological complete response or the duration of clinical complete response | 2023/12-2025/12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of ctDNA changes with 2 years PFS | Correlation of ctDNA changes with 2 years of progression-free survival after recived immunotherapy | 2023/12-2025/12 |
Evaluation of the F&P Caramel Nasal Mask, US, 2023

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical investigation is to evaluate the performance and safety of the F&P Caramel nasal mask in a home environment.

Official Title
-----------------
Evaluation of the F&P Caramel Nasal Mask, US, 2023

Conditions
-----------------
Obstructive Sleep Apnea

Intervention / Treatment
-----------------
* Device: F&P Caramel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Persons who are ≥22 years of age Persons who weigh ≥66 pounds Persons who have been prescribed PAP therapy by a physician Persons who are existing nasal mask or sub-nasal mask users with ≥3 months of use prior to enrolment in the clinical trial Persons who are compliant with PAP therapy for ≥4 hours per night for ≥70% of nights for a 14-day period within 30 days prior to enrolment in the clinical trial Persons who are fluent in spoken and written English Persons who possess the capacity to provide informed consent Exclusion Criteria: Persons who are intolerant to PAP therapy Persons who possess, or suffer from, anatomical or physiological conditions which make PAP therapy inappropriate Persons who are required to use PAP therapy for >12 hours per day or for extensive periods, not including sleep or naps Persons who are trying to get pregnant, are pregnant, or think they may be pregnant Persons who have an IPAP pressure of >30 cmH2O if on BPAP Persons who use a PAP therapy device for the delivery of medicines, except supplemental oxygen Persons who use a PAP therapy device that does not possess data recording capabilities to capture AHI and a numerical indicator of leak that is accessible to the investigation site

Ages Eligible for Study
-----------------
Minimum Age: 22 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: F&P Caramel|Nasal mask|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Apnea-Hypopnea Index | Acceptable maintenance or lower (improved score) from baseline. Scores below 5 indicate a better outcome. | 14±5 days | 
| Epworth Sleepiness Scale | Acceptable maintenance or lower (improved score) from baseline. Scores below 11 indicate a better outcome. | 14±5 days |